<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        188-276-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        NOOTROPIL 800 MG FILM COATED
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PIRACETAM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        800
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        27.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="U.C.B." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            U.C.B.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06BX03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Nootropil film coated tablet contains the active ingredient piracetam. It belongs to the nootropic class of drugs, which support cognitive processes like learning, concentration, attention and awareness. Nootropil FCT protects and restores the cognitive functions in patients with various brain lesions, e.g. caused by lack of oxygen or intoxication, and prevents changes in brain function and efficiency as a result of lack of oxygen.</p><p>In adults, Nootropil FCT is used for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the symptomatic treatment of the <em>psycho-organic syndrome</em> (whose features are memory loss, attention disorders and lack of drive)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of <em>myoclonus </em>(uncontrollable muscle jerks and twitches)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of <em>vertigo</em> (dizziness and spinning sensation) and associated disorders of balance - with the exception of dizziness of <em>vasomotor</em> or psychic origin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the prophylaxis of <em>sickle cell vaso-occlusive crises </em>(painful complication of a hereditary disorder of the red blood cells called <em>sickle-cell disease</em>)</p><p>In children, Nootropil FCT is used for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the treatment of <em>dyslexia </em>(reading disorder) - in combination with appropriate measures such as speech therapy (logopedics)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; the prophylaxis of <em>sickle cell vaso-occlusive crises </em>(painful complication of a hereditary disorder of the red blood cells called <em>sickle-cell disease</em>)</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Don&rsquo;t take </strong><strong>Nootropil FCT</strong><strong> </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>allergic</strong> (<em>hypersensitive</em>) to piracetam, other pyrrolidone derivatives, or any other ingredients of Nootropil FCT (listed in Section 6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>severe kidney disease</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have had a <strong>brain haemorrhage</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>Huntington&lsquo;s disease</strong> also known as Huntington&lsquo;s Chorea</p><p>&egrave;&nbsp;&nbsp; If you think any of these apply to you,<strong> don&rsquo;t take Nootropil FCT</strong> until you have checked with your doctor.</p><p><strong>Take special care with Nootropil FCT</strong><strong> </strong></p><p>Before you take Nootropil FCT your doctor needs to know:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you are <strong>taking any other medicines</strong> (see <em>Other medicines and Nootropil FCT</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>kidney problems</strong>, your doctor may adjust your dose of Nootropil FCT</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had any <strong>bleeding problems </strong>such as severe haemorrhage or bleeding disorder</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have <strong>gastric ulceration</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; if you have to undergo <strong>surgery </strong>or have recently had one,<strong> </strong>including <strong>dental surgery</strong></p><p>&egrave;&nbsp;&nbsp; <strong>Check with your doctor </strong>if you think any of these may apply to you<strong>. </strong>Your doctor will decide whether Nootropil FCT is suitable for you.</p><p><strong>Conditions you need to look out for</strong></p><p>Medicines like Nootropil FCT can cause <strong>severe allergic reactions</strong>. You must look out for certain symptoms while you are taking Nootropil FCT to reduce the risk of any problems. See <em>Conditions you need to look out for </em>in Section 4.</p><p><strong>Other medicines and Nootropil FCT</strong><strong> </strong></p><p><strong>Tell your doctor or pharmacist if you&#39;re taking any other medicines</strong>, if you&rsquo;ve taken any recently, or if you start taking new ones. This includes medicines bought without a prescription.</p><p>Some other medicines may affect how Nootropil FCT works or make it more likely that you&rsquo;ll have side effects. Nootropil FCT can also affect how some other medicines work. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>thyroid extract </strong>or <strong>thyroxine </strong>(used to treat <strong>thyroid hormone deficiency</strong>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>anticoagulants</strong> (used to prevent <strong>blood clots</strong>) such as warfarin or acenocoumarol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; <strong>platelet antiaggregant </strong>(used mostly to prevent <strong>heart problems</strong>) such as low dose acetylsalicylic acid</p><p>&egrave;&nbsp;&nbsp; <strong>Tell your doctor or pharmacist</strong> if you are taking any of these.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are<strong> pregnant</strong>, or <strong>think you could be, </strong>or if you are <strong>planning to become pregnant</strong>:</p><p>&egrave;&nbsp;&nbsp; <strong>Don&rsquo;t take Nootropil FCT</strong> without checking with your doctor.</p><p><strong>Your doctor </strong>will consider the benefit to you and the risk to your baby of taking Nootropil FCT while you&#39;re pregnant.</p><p><strong>Nootropil FCT should not be used during</strong> <strong>breast-feeding</strong>. The ingredients in Nootropil FCT can pass into breast milk, and so may harm your baby.</p><p>&egrave;&nbsp;&nbsp; <strong>If you are breast-feeding, you must check with your doctor</strong> before you take Nootropil FCT.<strong> </strong></p><p><strong>Driving and using machines</strong></p><p><strong>Nootropil FCT can make you shaky, drowsy or sleepy</strong> and have other side effects that make you less alert.</p><p>&egrave;&nbsp;&nbsp; <strong>Don&rsquo;t drive or use machines</strong> unless you are sure you&rsquo;re not affected.</p><p><strong>Nootropil FCT 400mg capsules contains the colorant Sunset Yellow</strong></p><p>May cause allergic-type reactions.</p><p>&egrave;&nbsp;&nbsp; <strong>Check with your doctor </strong>that Nootropil FCT is suitable for you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>How much to take </strong></p><p><strong>Always take Nootropil FCT exactly as your doctor has told you to.</strong> Check with your doctor or pharmacist if you&#39;re not sure.</p><p><strong>Adults</strong></p><p><em><u>Symptomatic treatment of psycho-organic syndromes</u></em></p><p><strong>The usual dose</strong> of Nootropil FCT is 2400mg (2.4g) up to 4800mg (4.8g) a day, taken in two or three divided doses.</p><p><em><u>Treatment of myoclonus</u></em></p><p><strong>The usual starting dose</strong> of Nootropil FCT is 7200mg (7.2g) a day, increasing by 4800mg (4.8g) every three or four days up to a maximum of 24000mg (24g) a day, taken in two or three divided doses.</p><p><em><u>Treatment of vertigo</u></em></p><p><strong>The usual dose</strong> of Nootropil FCT is 2400mg (2.4g) up to 4800mg (4.8g) a day, taken in two or three divided doses.</p><p><em><u>Prophylaxis of sickle cell vaso-occlusive crises</u></em><br />Your doctor will decide on the correct dose of Nootropil FCT depending on your weight.</p><p><strong>The usual dose</strong> of Nootropil FCT is 160 mg/kg a day, taken in four divided doses.</p><p>If you are <strong>elderly</strong> or have <strong>kidney problems,</strong> you may have your dose reduced.</p><p><strong>Children</strong></p><p><em><u>Dyslexia in combination with appropriate measures such as speech therapy</u></em></p><p><strong>The usual dose</strong> of Nootropil FCT, for school age children (from 8 years old) and adolescents, is 3200mg (3.2g) taken twice a day (in the morning and in the evening), usually during the whole period of the school year.</p><p><em><u>Prophylaxis of sickle cell vaso-occlusive crises</u></em></p><p>Your doctor will decide on the correct dose of Nootropil FCT for your child, depending on the weight of the child.&nbsp; <strong>The usual dose</strong> of Nootropil FCT, for children from 3 years old onwards, is 160 mg/kg a day taken in four divided doses.</p><p>If your child has <strong>kidney problems,</strong> he or she may may need to take a lower dose.</p><p><strong>Don&rsquo;t take any more Nootropil FCT than your doctor has recommended</strong>. It may take a few weeks for Nootropil FCT to work for you.</p><p><strong>How to take</strong></p><p><strong>Tablets</strong></p><p>Swallow the tablet whole, with some water.</p><p>You can take Nootropil FCT with or without food.</p><p>&nbsp;</p><p>Don&rsquo;t break or chew the tablets as piracetam has a very bitter taste.</p><p><strong>If you forget to take Nootropil FCT</strong></p><p><strong>Don&#39;t take an extra dose to make up for a missed dose</strong>. Just take your next dose at the usual time.<strong> </strong></p><p><strong>If you take too much Nootropil FCT</strong></p><p>&egrave;&nbsp;&nbsp; <strong>Contact your doctor or pharmacist for advice.</strong> If possible, show them the Nootropil FCT pack.</p><p><strong>Don&rsquo;t stop </strong><strong>Nootropil FCT without advice</strong></p><p><strong>Take Nootropil FCT for as long as your doctor recommends</strong>. Don&rsquo;t stop unless your doctor advises you to. If you are suffering from myoclonus, abruptly stopping your medicine may cause twitching and jerking or fits (<em>seizures</em>).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Nootropil FCT can cause side effects, but not everybody gets them.</p><p><strong>Conditions you need to look out for</strong></p><p><strong>Severe allergic reaction. </strong>Signs include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; raised and itchy rash (hives)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; swelling, sometimes of the face or mouth (angioedema), causing difficulty in breathing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; collapse or loss of consciousness.</p><p>&egrave;&nbsp;&nbsp; <strong>Contact a doctor immediately </strong>if you get these symptoms.<strong> </strong></p><p>The side effects that have occurred in people using Nootropil FCT are:</p><p><strong>Common side effects</strong></p><p>These may affect <strong>up to 1 in 10 </strong>people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; weight increased</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; nervousness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; unusually overactive (excessive muscular activity, <em>hyperkinesia</em>)</p><p><strong>Uncommon side effects</strong></p><p>These may affect <strong>up to 1 in 100</strong> people:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling drowsy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak</p><p><strong>Other side effects</strong></p><p>Other side effects have occurred in a very small number of people, but their exact frequency is unknown:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; allergic reaction, angioedema, skin rash, itching, hives (see &lsquo;Severe allergic reactions&rsquo; earlier in Section 4)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; spontaneous bleeding caused by defects in your blood clotting mechanism</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; agitation, anxiety, confusion, seeing or hearing things that are not really there (<em>hallucination</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; loss of coordinated bodily movements, difficulty balancing and unsteadiness when standing</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; worsening of epilepsy (condition where you have repeated fits or convulsions)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; headache, difficulty in sleeping, spinning sensation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain, diarrhoea, feeling sick (<em>nausea</em>), being sick (<em>vomiting</em>)</p><p>&egrave;&nbsp;&nbsp; <strong>Tell your doctor or pharmacist</strong> if any of the side effects listed becomes <strong>severe or troublesome</strong>, or if you notice any side effects not listed in this leaflet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; <strong>Keep out of the reach and sight of children.</strong></p><p>&bull; Do not use Nootropil FCT after the expiry date which is stated on the pack after &lsquo;Exp&rsquo;.</p><p>&bull; Store Nootropil FCT at below 30&deg;C.</p><p>&bull; If your doctor tells you to stop taking Nootropil FCT, it is important to return any remnants which are left over to your pharmacist.</p><p>&bull; Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&nbsp;Active ingredients:</p><p>Each tablet contains 800 mg of piracetam</p><p>&bull; Non-active ingredients:</p><p>Macrogol 6000, Colloidal anhydrous silica, Magnesium stearate, Sodium</p><p>croscarmellose, Hydroxypropyl methylcellulose, Titanium dioxide (E171), Macrogol 400, and water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                White, oblong, film-coated tablet, with a bisect line, marked N/N.
Each pack contains 30 Film-coated tablets of piracetam 800 mg.

Not all presentations are available in every country.


Nootropil is a trademark owned by or licensed to the GSK group of companies 
© 2020 GSK group of companies. All rights reserved.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufactured by:</strong></p><p>UCB S.A. PHARMA SECTOR, BRAINE-L&bull; AL LEUD. BELGIUM</p><p><strong>Marketing Authorization Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.* Jeddah, KSA</p><p>Address: P.O. Box 22617 Jeddah 21416 &ndash; Kingdom of Saudi Arabia</p><p>*member of the GlaxoSmithKline group of companies</p><p><strong>For any information about this medicinal product, please contact: </strong></p><p><strong>GlaxoSmithKline - Head Office, Jeddah </strong></p><p>Tel: +966-12-6536666</p><p>Mobile: +966-56-904-9882</p><p>Email: gcc.medinfo@gsk.com&nbsp;</p><p>website: https://gskpro.com/en-sa/</p><p>P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: 03
Date of issue: 25 January 2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">ﻧﻮﺗﺮوﭘـﻴﻞ أقراص مغلفة بغلاف غشائي يحتوي على المادة الفعالة ﭘـﲑاﺳﻴﺘﺎم. ﻳﻨﺘﻤﻲ إﱃ فئة المنشطات الذهنية التي تدعم العمليات الإدراكية مثل التعلم، والتركيز، والانتباه، والوعي. ﻧﻮﺗﺮوﭘـﻴﻞ يحمي ويعيد الوظائف الإدراكية في المرضى الذين يعانون من أضرار في الدماغ الناشئة عن نقص الاكسجين أو التسمم، كما يمنع حدوث تغييرات في وظائف المخ وكفاءته نتيجة نقص الاكسجين.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>في اﻟﺒﺎﻟﻐﻴﻦ (ﻧﻮﺗﺮوﭘـﻴﻞ يستعمل في الحالات التالية):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج أعراض المتلازمة النفسية العضوية (psycho-organic syndrome) (التي تتمثل سماتها في فقدان الذاكرة، واضطرابات الانتباه، وضعف القدرة على القيادة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج الرمع العضلي (رعشة وخلجان لا يمكن السيطرة عليها ﰲ اﻟﻌﻀﻼت)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻋﻼج اﻟﺪوار (الدوخة والإحساس بالدوار) وما يصاحبها من اضطرابات في التوازن باستثناء الدوخة الحركية أو النفسية المنشأ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﻮﻗﺎﻳﺔ ﻣﻦ&nbsp; اﻧﺴﺪاد اﻷوﻋﻴﺔ اﻟﺪﻣﻮﻳﺔ اﻟﺼﻐﲑة ﻧﺘﻴﺠﺔ أزﻣﺔ ﻓﻘﺮ اﻟﺪم اﳌﻨﺠﻠﻲ (مضاعفات مؤلمة لاضطراب وراثي في خلايا الدم الحمراء تسمى مرض فقر الدم المنجلي)</p><p dir="RTL"><strong>في الأطفال (ﻧﻮﺗﺮوﭘـﻴﻞ يستعمل في الحالات التالية):</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علاج (ﻋﺴﺮ اﻟﻘﺮاءة) بالاقتران مع الاجراءات المناسبة مثل ﻋﻼج اﻟﺘﺨﺎﻃﺐ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻟﻮﻗﺎﻳﺔ ﻣﻦ&nbsp; اﻧﺴﺪاد اﻷوﻋﻴﺔ اﻟﺪﻣﻮﻳﺔ اﻟﺼﻐﲑة ﻧﺘﻴﺠﺔ أزﻣﺔ ﻓﻘﺮ اﻟﺪم اﳌﻨﺠﻠﻲ (مضاعفات مؤلمة لاضطراب وراثي في خلايا الدم الحمراء تسمى مرض فقر الدم المنجلي)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﻻ ﻳﺠﻮز ﺗﻨﺎول ﻧﻮﺗﺮوﭘـﻴﻞ ﻓﻲ اﻟﺤﺎﻻت اﻟﺘﺎﻟﻴﺔ:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا ﻛﻨﺖ ﻣﺼﺎﺑﺎً ﲝﺴﺎﺳﻴﺔ (ﻣﻔﺮط اﳊﺴﺎﺳﻴﺔ) ﻟﻠﭙـﲑاﺳﻴﺘﺎم، أو أي ﻣﻦ اﳌﻜﻮﻧﺎت اﻷﺧﺮى ﺑﻨﻮﺗﺮوﭘـﻴﻞ (ﻣﺪرج ﺑﺎﻟﻔﻘﺮة ٦)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻟﺪﻳﻚ إعتلال ﺷﺪﻳﺪ ﰲ اﻟﻜﻠﻰ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻧﺰﻳﻒ داﺧﻞ اﳌﺦ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻟﺪﻳﻚ ﺣﺎﻟﺔ ﺗﺪﻋﻰ ﺗﻨﺎذر ﻫﻨﺘﻨﺠﺘﻮن</p><p dir="RTL">&nbsp;</p><p dir="RTL">&ccedil;&nbsp; إذا كنت تعتقد أن أي مما سبق ينطبق عليك، لا تتناول نوﺗﺮوﭘـﻴﻞ قبل اﻟﺘﺤﺪث ﻣﻊ اﻟﻄﺒﻴﺐ أو اﻟﺼﻴﺪﱄ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﻳﺠﺐ ﺗﻮﺧﻲ اﻟﺤﺬر اﻟﺸﺪﻳﺪ ﻋﻨﺪ اﺳﺘﻌﻤﺎل ﻧﻮﺗﺮوﭘـﻴﻞ:</strong><strong>&shy;</strong></p><p dir="RTL"><strong>قبل تناول ﻧﻮﺗﺮوﭘـﻴﻞ، يحتاج طبيبك إلى معرفة:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول أي أدوية أخرى (انظر إلى الأدوية الأخرى وﻧﻮﺗﺮوﭘـﻴﻞ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا&nbsp; ﻛﻨﺖ ﺗﻌﺎﱐ ﻣﻦ ﻣﺸﺎﻛﻞ ﺑﺎﻟﻜﻠﻰ (قد يقوم طبيبك بتعديل جرعة ﻧﻮﺗﺮوﭘـﻴﻞ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالة الإصابة سابقاً بنزيف، كنزيف حاد أو اضطراب نزيفي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك قرحة في المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان عليك الخضوع لعملية جراحية أو أجريت عملية جراحية مؤخراً (بما في ذلك جراحة الأسنان)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&ccedil;</strong><strong> استشر طبيبك</strong> إذا كنت تظن أن ما سبق ينطبق عليك، سيقرر طبيبك ما إذا كان نوﺗﺮوﭘـﻴﻞ مناسباً لك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات يجب التأكد منها:</strong></p><p dir="RTL">يمكن أن تسبب الأدوية مثل ﻧﻮﺗﺮوﭘـﻴﻞ <strong>ردود فعل تحسسية شديدة</strong>.</p><p dir="RTL">يجب الانتباه إلى بعض الأعراض أثناء تناولك ﻧﻮﺗﺮوﭘـﻴﻞ لتقليل حدوث أي مشاكل. (انظر إلى حالات تحتاج الحذر منها &quot;الفقرة 4&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأدوية الأخرى وﻧﻮﺗﺮوﭘـﻴﻞ</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا كنت تتناول أي أدوية أخرى، </strong>إذا تناولت أي أدوية مؤخراً، أو بدأت ﺑﺎستخدام أدوية جديدة. هذا يشمل الأدوية بدون وصفة طبية.</p><p dir="RTL">بعض الأدوية تؤثر على طريقة عمل ﻧﻮﺗﺮوﭘـﻴﻞ، أو تزيد من احتمالية حدوث آﺛﺎر جانبية لدى الأشخاص.</p><p dir="RTL">ﻧﻮﺗﺮوﭘـﻴﻞ قد يؤثر على أيضاً على طريقة عمل الأدوية الأخرى. هذا يشمل:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ﺧﻼﺻﺔ اﻟﻐﺪة اﻟﺪرﻗﻴﺔ</strong> أو <strong>اﻟﺜﲑوﻛﺴﲔ</strong> (تستخدم لعلاج نقص هرمون الغدة الدرقية)</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ﻣﻀﺎدات ﲣﺜﺮ اﻟﺪم</strong> (تستخدم لمنع <strong>تجلط الدم</strong>) ﻣﺜﻞ اﻟﻮارﻓﺎرﻳﻦ أو اﻷﺳﻴﻨﻮﻛﻮﻣﺎرول</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>مضاد تكدس الصفائح الدموية</strong> (يستخدم غالباً لمنع <strong>مشاكل القلب</strong>) مثل جرعة منخفضة من حمض الأسيتيل ساليسيليك</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي</strong> إذا كنت تتناول أياً مما سبق.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>اﻟﺤﻤﻞ واﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﻴﻌﻴﺔ</strong></p><p dir="RTL">إذا كنتِ <strong>حامل</strong>، أو قد <strong>تكونين حامل</strong>، أو<strong> تخططين للحمل</strong>.</p><p dir="RTL">&ccedil; <strong>لا تتناولي</strong> ﻧﻮﺗﺮوﭘـﻴﻞ دون استشارة طبيبكِ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيقرر <strong>الطبيب</strong> المنافع التي تعود عليك والمضار التي قد يتعرض لها طفلك من تناولك لنوﺗﺮوﭘـﻴﻞ أثناء الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﻻ ﳚﻮز اﺳﺘﻌﻤﺎل ﻧﻮﺗﺮوﭘـﻴﻞ أﺛﻨﺎء اﻟﺮﺿﺎﻋﺔ اﻟﻄﺒﻴﻌﻴﺔ</strong>، يمكن أن تنتقل المواد الفعالة من ﻧﻮﺗﺮوﭘـﻴﻞ إلى حليب الثدي وقد تؤثر على طفلك.</p><p dir="RTL">&ccedil; <strong>إذا كنتِ تقومين ﺑﺎلرضاعة الطبيعية، تحدثي إلى طبيبك قبل </strong>تناول ﻧﻮﺗﺮوﭘـﻴﻞ.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>اﻟﺘﺄﺛﻴﺮ ﻋﻠﻰ اﻟﻘﺪرة ﻋﻠﻰ ﻗﻴﺎدة اﻟﺴﻴﺎرات واﺳﺘﻌﻤﺎل اﻟﻤﺎﻛﻴﻨﺎت</strong></p><p dir="RTL">ﻧﻮﺗﺮوﭘـﻴﻞ ﻗﺪ ﻳﺴﺒﺐ دوﺧﺔ وارﲡﺎف أو قد يسبب النعاس. وله آثار جانبية أخرى قد تجعلك أقل يقظة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا يجوز قيادة السيارات أو تشغيل الماكينات </strong>إلا إذا كنت متأكداً من عدم ﺗﺄثرك ﺑﺎلعقار .</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحتوي كبسولات </strong><strong>ﻧﻮﺗﺮوﭘـﻴﻞ 400 ملجم على ملونات صفراء</strong> قد تسبب ردود فعل تحسسية.</p><p dir="RTL">&ccedil; <strong>استشر طبيبك</strong> إذا ما كان ﻧﻮﺗﺮوﭘـﻴﻞ مناسباً لك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الجرعة التي يجب تناولها</strong></p><p dir="RTL"><strong>نوﺗﺮوﭘـﻴﻞ ﳚﺐ ﺗﻨﺎوﻟﻪ داﺋﻤﺎً وﻓﻘﺎً ﻟﺘﻌﻠﻴﻤﺎت اﻟﻄﺒﻴﺐ</strong>. ﳚﺐ اﻟﺮﺟﻮع إﱃ اﻟﻄﺒﻴﺐ أو اﻟﺼﻴﺪﱄ إذا ﱂ ﺗﻜﻦ متأكداً.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>البالغين:</strong></p><p dir="RTL"><em><u>علاج أعراض المتلازمات النفسية-العضوية (</u></em><em><u>psycho-organic syndromes</u></em><em><u>)</u></em><em><u>:</u></em></p><p dir="RTL"><strong>اﳉﺮﻋﺔ اﻟمعتادة </strong>من ﻧﻮﺗﺮوﭘـﻴﻞ هي 2400 ملجم (2,4 جم) بحد أقصى 4800 ملجم (4,8 جم) في اليوم، تؤخذ على جرعتين أو 3 جرعات مقسمة.</p><p dir="RTL"><em><u>علاج ﻧﻮﺑﺎت اﻟﺮﻣﻊ اﻟﻌﻀﻠﻲ اﻟﻘﺸﺮي: </u></em></p><p dir="RTL"><strong>الجرعة المعتادة الأولى</strong> من ﻧﻮﺗﺮوﭘـﻴﻞ هي 7200 ملجم (7,2 جم) في اليوم، تزداد بمقدار 4800 ملجم (4,8 جم) كل 3 أو 4 أيام بحد أقصى 24000 ملجم (24 جم) في اليوم، تؤخذ على جرعتين أو 3 جرعات مقسمة.</p><p dir="RTL"><em><u>ﻋﻼج اﻟﺪوار: </u></em></p><p dir="RTL"><strong>اﳉﺮﻋﺔ المعتادة</strong> من ﻧﻮﺗﺮوﭘـﻴﻞ ﻫﻲ 2400 ملجم (٢,٤ ﺟﻢ) &nbsp;بحد أقصى 4800 ملجم (٤,٨ ﺟﻢ) في اليوم، تؤخذ ﻋﻠﻰ جرعتين أو 3 جرعات مقسمة.</p><p dir="RTL"><em><u>اﻟﻮﻗﺎﻳﺔ ﻣﻦ اﻧﺴﺪاد اﻷوﻋﻴﺔ اﻟﺪﻣﻮﻳﺔ اﻟﺼﻐﲑة ﻧﺘﻴﺠﺔ أزﻣﺔ ﻓﻘﺮ اﻟﺪم اﳌﻨﺠﻠﻲ:</u></em></p><p dir="RTL">سوف يقرر الطبيب الجرعة الصحيحة من ﻧﻮﺗﺮوﭘـﻴﻞ بناءاً على وزنك.</p><p dir="RTL"><strong>اﳉﺮﻋﺔ المعتادة </strong>من ﻧﻮﺗﺮوﭘـﻴﻞ ﻫﻲ 160 ملجم/كجم في اليوم، تؤخذ ﻋﻠﻰ 4 جرعات مقسمة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت <strong>كبيراً في السن</strong>، أو لديك <strong>مشاكل في الكلى</strong>، فقد يتم تقليل جرعتك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال:</strong></p><p dir="RTL"><em><u>عسر اﻟﻘﺮاءة إﱃ ﺟﺎﻧﺐ ﻣﻌﺎﻳﲑ أﺧﺮى ﻣﻨﺎﺳﺒﺔ ﻣﺜﻞ ﻋﻼج اﻟﺘﺨﺎﻃﺐ: </u></em></p><p dir="RTL"><strong>اﳉﺮﻋﺔ المعتادة </strong>من ﻧﻮﺗﺮوﭘـﻴﻞ، للأﻃﻔﺎل بسن المدرسة (ﻣﻦ ﺳﻦ ٨ ﺳﻨﻮات) والمراهقين، ﻫﻲ 3200 ملجم (٣,٢ﺟﻢ) تؤخذ مرتين يومياً (صباحاً ومساءاً) وذﻟﻚ ﻟﻜﺎﻣﻞ ﻓﱰة اﻟﻌﺎم اﻟﺪراﺳﻲ.</p><p dir="RTL"><em><u>اﻟﻮﻗﺎﻳﺔ ﻣﻦ اﻧﺴﺪاد اﻷوﻋﻴﺔ اﻟﺪﻣﻮﻳﺔ اﻟﺼﻐﲑة ﻧﺘﻴﺠﺔ أزﻣﺔ ﻓﻘﺮ اﻟﺪم اﳌﻨﺠﻠﻲ:</u></em></p><p dir="RTL">ﺳﻮف يقرر ﻃﺒﻴﺒﻚ الجرعة الصحيحة من ﻧﻮﺗﺮوﭘـﻴﻞ لطفلك على حسب وزن طفلك.</p><p dir="RTL"><strong>الجرعة المعتادة</strong> من نوﺗﺮوﭘـﻴﻞ للأطفال من سن 3 سنوات فما فوق هي 160 ملجم/كجم يومياً، تؤخذ على 4 جرعات مقسمة.</p><p dir="RTL">إذا كان لدى طفلك <strong>مشاكل في الكلى</strong>، فقد يتم تقليل جرعته.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>ﻛﻴﻔﻴﺔ ﺗﻨﺎول ﻧﻮﺗﺮوﭘـﻴﻞ</strong></p><p dir="RTL"><strong>الأقراص</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﳚﺐ اﺑﺘﻼﻋﻬﺎ ﻛﺎﻣﻠﺔً ﻣﻊ ﻛﻮب ﻣﻦ اﳌﺎء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن تناول نوﺗﺮوﭘـﻴﻞ مع أو بدون الطعام</p><p dir="RTL">اﻷﻗﺮاص ﻻ ﳚﻮز ﻛﺴﺮﻫﺎ أو ﻣﻀﻐﻬﺎ ﻧﻈﺮاً ﻷن ﻃﻌﻢ اﻟـﭙـﲑاﺳﻴﺘﺎم ﻣﺮ ﺟﺪاً</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا ﻧﺴﻴﺖ ﺗﻨﺎول ﻧﻮﺗﺮوﭘـﻴﻞ</strong></p><p dir="RTL"><strong>لا تتناول ﺟﺮﻋﺔ ﻣﻀﺎﻋﻔﺔ ﻟﻠﺘﻌﻮﻳﺾ ﻋﻦ ﺟﺮﻋﺔ ﻣﻨﺴﻴﺔ، </strong>فقط ﺗﻨﺎول اﳉﺮﻋﺔ اﻟﺘﺎﻟﻴﺔ ﰲ ﻣﻮﻋﺪﻫﺎ اﳌﻌﺘﺎد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا ﺗﻨﺎوﻟﺖ أﻛﺜﺮ ﻣﻤﺎ ﻳﺠﺐ ﺗﻨﺎوﻟﻪ ﻣﻦ ﻧﻮﺗﺮوﭘـﻴﻞ</strong></p><p dir="RTL"><strong>استشر الطبيب أو الصيدلي</strong>، إذا أمكن أظهر لهم ﻋﺒﻮة نوﺗﺮوﭘـﻴﻞ.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>لا توقف ﺗﻨﺎول ﻧﻮﺗﺮوﭘـﻴﻞ بدون مشورة</strong></p><p dir="RTL"><strong>تناول </strong><strong>ﻧﻮﺗﺮوﭘـﻴﻞ</strong><strong> طالما نصحك طبيبك بذلك</strong>. لاتوقف تناول الدواء إلا إذا نصحك طبيبك بذلك.</p><p dir="RTL">إذا كنت تعاني من الرمع العضلي، فإن التوقف المفاجئ عند تناول الدواء قد يسبب خلجان ، وارتعاشاً، أو نوبات (تشنجات).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﻛﺸﺄن ﻛﺎﻓﺔ اﻷدوﻳﺔ، ﻧﻮﺗﺮوﭘـﻴﻞ ﻗﺪ ﻳﺴﺒﺐ آﺛﺎراً ﺟﺎﻧﺒﻴﺔ، إﻻ أنها ﻻ ﺗﺼﻴﺐ ﻛﻞ ﻓﺮد.</p><p dir="RTL"><strong>حالات تحتاج الحذر منها:</strong></p><p dir="RTL"><strong>ردود ﻓﻌﻞ ﺗﺤﺴﺴﻴﺔ شديدة. </strong>الأعراض تتضمن:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح ﺟﻠﺪي ومثير للحكة (ﺷﺮى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺗﻮرم، أحياناً ﻓﻲ الوجه أو اﻟﻔﻢ (وذﻣﺔ وعائية) يسبب صعوبة في التنفس</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الانهيار أو فقدان الوعي</p><p dir="RTL"><strong>&ccedil;</strong><strong> اتصل بطبيبك على الفور </strong>إذا كنت تعاني من أي من هذه الأعراض .</p><p dir="RTL">اﻵﺛﺎر اﻟﺠﺎﻧﺒﻴﺔ التي حدثت في الأشخاص الذين يستخدمون ﻧﻮﺗﺮوﭘـﻴﻞ هي:</p><p dir="RTL"><strong>الآثار الجانبية الشاﺋﻌﺔ (</strong>تصيب <strong>حتى فرد واحد من كل ١٠ أفراد</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زﻳﺎدة اﻟﻮزن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻋﺼﺒﻴﺔ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻓﺮط اﻟﻨﺸﺎط ﻋﻠﻰ ﳓﻮ ﻏﲑ ﻋﺎدي (نشاط عضلي مفرط، فرط الحركة)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية غير الشاﺋﻌﺔ (</strong>تصيب <strong>حتى فرد واحد من كل ١0٠ أفراد</strong><strong>)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﻛﺘﺌﺎب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺷﻌﻮر ﺑﺪوﺧﺔ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﺷﻌﻮر ﺑﻀﻌﻒ</p><p dir="RTL"><strong>الآثار الجانبية الأخرى:</strong></p><p dir="RTL">تم تسجيل آثار جانبية أخرى لدى عدد قليل جداً من الأشخاص، لكن شيوعها الدقيق غير معروف:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي، وذمة وعائية، وطفح جلدي، وحكة، وشرى (انظر إلى ردود ﻓﻌﻞ ﺗﺤﺴﺴﻴﺔ &quot;الفقرة 4&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف تلقائي ناجم عن عيوب في آلية تخثر الدم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻫﻴﺎج، ﻗﻠﻖ، ارﺗﺒﺎك، رؤﻳﺔ أو ﲰﺎع أﺷﻴﺎء ﻏﲑ ﻣﻮﺟﻮدة ﺑﺎﻟﻔﻌﻞ (هلوسة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻓﻘﺪان ﺗﻨﺎﺳﻖ ﺣﺮﻛﺎت اﳉﺴﻢ، اﺿﻄﺮاب ﺑﺎﻟﺘﻮازن، وعدم الثبات عند الوقوف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تفاقم الصرع (حالة قد تعاني فيها من نوبات أو تشنجات متكررة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صداع، صعوبة في النوم، إحساس بالدوار</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أﱂ في المعدة، إسهال، الشعور بالمرض (غثيان)، أو المرض (قيء)</p><p dir="RTL">&nbsp;</p><p dir="RTL">&ccedil; إذا أﺻﺒﺤﺖ أي ﻣﻦ اﻵﺛﺎر اﳉﺎﻧﺒﻴﺔ ﺧﻄﲑة، أو إذا ﻻﺣﻈﺖ أﻳﺔ آﺛﺎر ﺟﺎﻧﺒﻴﺔ ﻏﲑ ﻣﺪرﺟﺔ ﰲ ﻫﺬﻩ اﻟﻨﺸﺮة، <strong>ﻳﺮﺟﻰ اﻻﺗﺼﺎل ﺑﺎﻟﻄﺒﻴﺐ أو اﻟﺼﻴﺪﱄ.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>ﻳﺤﻔﻆ ﺑﻌﻴﺪاً ﻋﻦ ﻣﺘﻨﺎول وﻧﻈﺮ اﻷﻃﻔﺎل.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﳚﻮز اﺳﺘﻌﻤﺎل ﻧﻮﺗﺮوﭘـﻴﻞ ﺑﻌﺪ ﺗﺎرﻳﺦ اﻧﺘﻬﺎء اﻟﺼﻼﺣﻴﺔ اﳌﺒﲔ ﻋﻠﻰ اﻟﻌﺒﻮة ﺑﻌﺪ ﻛﻠﻤﺔ &quot;Exp&quot;.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﳚﺐ ﲣﺰﻳﻦ ﻧﻮﺗﺮوﭘـﻴﻞ ﰲ درجة حرارة أقل من 30&deg;م.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا أﺧﱪك اﻟﻄﺒﻴﺐ ﺑﻮﻗﻒ اﺳﺘﻌﻤﺎل ﻧﻮﺗﺮوﭘـﻴﻞ، ﻓﻤﻦ اﳌﻬﻢ إﻋﺎدة أي ﻛﻤﻴﺔ ﻣﺘﺒﻘﻴﺔ إﱃ اﻟﺼﻴﺪﱄ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻻ ﳚﻮز اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﻳﺔ ﰲ ﻣﻴﺎﻩ اﻟﺼﺮف اﻟﺼﺤﻲ أو اﳌﺨﻠﻔﺎت اﳌﻨـﺰﻟﻴﺔ. اﺳﺄل اﻟﺼﻴﺪﱄ ﻋﻦ&nbsp; ﻛﻴﻔﻴﺔ اﻟﺘﺨﻠﺺ ﻣﻦ اﻷدوﻳﺔ اﻟﱵ ﱂ ﺗﻌﺪ ﲝﺎﺟﺔ إﻟﻴﻬﺎ. ﻫﺬﻩ اﻟﺘﺪاﺑﲑ ﺗﺴﺎﻋﺪ ﻋﻠﻰ وﻗﺎﻳﺔ اﻟﺒﻴﺌﺔ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ﻋﻠﻰ ﻣﺎذا ﻳﺤﺘﻮي ﻧﻮﺗﺮوﭘـﻴﻞ</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اﳌﻜﻮﻧﺎت اﻟﻔﻌﺎﻟﺔ:</p><p dir="RTL">ﳛﺘﻮي ﻛﻞ ﻗﺮص ﻋﻠﻰ ٨٠٠ ﻣﻠﺠﻢ ﭘـﲑاﺳﻴﺘﺎم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ﻣﻜﻮﻧﺎت ﻏﲑ ﻓﻌﺎﻟﺔ:</p><p dir="RTL">ﻣﺎﻛﺮوﺟﻮل ٦٠٠٠، ﺳﻴﻠﻴﻜﺎ ﻏﺮوﻳﺔ ﻻ ﻣﺎﺋﻴﺔ، ﺳﺘﻴﺎرات اﳌﺎﻏﻨﺴﻴﻮم، ﻛﺮوﺳﻜﺎرﻣﻴﻠﻮز اﻟﺼﻮدﻳﻮم، ﻫﻴﺪروﻛﺴﻲ ﭘﺮوﭘـﻴﻞ ﻣﻴﺜﻴﻞ ﺳﻴﻠﻴﻠﻮز، ﺛﺎﱐ أﻛﺴﻴﺪ اﻟﺘﻴﺘﺎﻧﻴﻮم (E171)، ﻣﺎﻛﺮوﺟﻮل ٤٠٠، وﻣﺎء</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص ﺑﻴﻀﺎء اﻟﻠﻮن، ﻣﺴﺘﻄﻴﻠﺔ اﻟﺸﻜﻞ، ﻣﻐﻠﻔﺔ ﺑﻜﺴﻮة ﻏﺸﺎﺋﻴﺔ، ﻣﻊ ﺧﻂ ﻣﻨﺼﻒ، ﻣﻨﻘﻮش ﻋﻠﻴﻬﺎ اﳊﺮوف N/N.</p><p dir="RTL">ﻛﻞ ﻋﺒﻮة ﲢﺘﻮي ﻋﻠﻰ ٣٠ ﻗﺮص ﻣﻐﻠﻔﺔ ﺑﻜﺴﻮة ﻏﺸﺎﺋﻴﺔ ﻣﻦ ﭘـﲑاﺳﻴﺘﺎم ٨٠٠ ﻣﻠﺠﻢ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ﻻ ﺗﺘﻮﻓﺮ ﲨﻴﻊ أﺷﻜﺎل اﻟﻌﺒﻮات ﰲ ﻛﻞ ﺑﻠﺪ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نوﺗﺮوﭘـﻴﻞعلامة تجارية مملوكة أو مرخصة لمجموعة شركات جلاكسو سميث كلاين.</p><p dir="RTL">&copy; 2020 جلاكسو سميث كلاين، جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ﺗﺼﻨﻴﻊ:</strong></p><p dir="RTL">ﻳﻮ ﺳﻲ ﰊ إس.أﻳﻪ. ﻗﻄﺎع اﻟﻔﺎرﻣﺎ، ﺑﺮﻳﻦ-لـ &bull; أل ﻟﻴﻮد. ﺑﻠﺠﻴﻜﺎ</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة المالكة لرخصة التسويق</strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، السعودية</p><p dir="RTL">العنوان: صندوق بريد ٢٢٦١٧ ، جدة ٢١٤١٦ ، المملكة العربية السعودية</p><p dir="RTL">*عضو في مجموعة شركات جلاكسو سميث كلاين</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>للإستفسار عن أي معلومات عن هذا المستحضر الدوائي، يرجى الإتصال بالأرقام التالية:</strong></p><p dir="RTL">جلاكسو سميث كلاين &ndash; المكتب الرئيسي، جدة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هاتف: 6536666-12-966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جوال: 9049882-56-966+</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: gcc.medinfo@gsk.com</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://gskpro.com/en-sa/</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ص.ب. 55850، جدة 21544، المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            إﺻﺪار رﻗﻢ: ٠3 
ﺗﺎرﻳﺦ اﻹﺻﺪار: 25 يناير ٢٠١7
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Piracetam, 800 mg, film-coated tablet
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Piracetam, 800 mg, film-coated tablet
Each film-coated tablet contains 800 mg of piracetam

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Piracetam, 800 mg, film-coated tablet
White, oblong, film-coated tablet, with a bisect line, marked N/N on one side and plain on the other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults</p><p>Piracetam is indicated for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; symptomatic treatment of the psycho-organic syndrome whose features, improved by treatment, are memory loss, attention disorders and lack of drive,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of cortical myoclonus, alone or in combination,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of vertigo and associated disorders of balance, with the exception of dizziness of vasomotor or psychic origin,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prophylaxis and remission of sickle cell vaso-occlusive crises.</p><p>Children</p><p>Piracetam is indicated for:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; treatment of dyslexia, in combination with appropriate measures such as speech therapy,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; prophylaxis and remission of sickle cell vaso-occlusive crises.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Oral formulations</em></p><p>Piracetam may be taken with or without food. The film-coated tablets should be swallowed with liquid. Granules for oral solution should be dissolved in liquid. It is recommended to take the daily dose in two to four sub-doses.</p><p><em>Parenteral formulations</em></p><p>When parenteral administration is needed (e.g. swallowing difficulties, unconsciousness) piracetam can be administered intravenously at the same recommended daily dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution for injection will be administered intravenously over several minutes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The solution for infusion will be administered continuously at the recommended daily dose over a 24 &shy;hour period.</p><p>Route of Administration</p><p><em>Oral formulations</em></p><p>For oral use.</p><p><em>Parenteral formulations</em></p><p>For intravenous use.</p><p>Adults</p><p><em>Symptomatic treatment of psycho-organic syndromes</em></p><p>The recommended daily dose ranges from 2.4&nbsp;g up to 4.8&nbsp;g, in two or three sub-doses.</p><p><em>Treatment of myoclonus of cortical origin</em></p><p>The daily dosage should begin at 7.2&nbsp;g, increasing by 4.8&nbsp;g every three or four days up to a maximum of 24&nbsp;g, in two or three divided doses. Treatment with other anti-myoclonic medicinal products should be maintained at the same dosage. Depending on the clinical benefit obtained, the dosage of other such medicinal products should be reduced, if possible. The dosage must be set individually for each patient by a therapeutic trial.</p><p>Once started, treatment with piracetam should be continued for as long as the original cerebral disease persists. In patients with an acute episode, spontaneous evolution may occur over time and an attempt should be made every 6&nbsp;months to decrease or discontinue the medicinal treatment. This should be done by reducing the dose of piracetam by 1.2&nbsp;g every two days (every three or four days in the case of a Lance- Adams syndrome, in order to prevent the possibility of sudden relapse or withdrawal seizures).</p><p><em>Treatment of vertigo</em></p><p>The recommended daily dose ranges from 2.4&nbsp;g to 4.8&nbsp;g, in two or three divided doses.</p><p><em>Prophylaxis and remission of sickle cell vaso-occlusive crises</em></p><p>The recommended daily dose for prophylaxis is 160&nbsp;mg/kg, orally, in four divided doses.</p><p>The recommended daily dose for remission is 300&nbsp;mg/kg intravenously, in four divided doses. For sickle cell anaemia the prophylactic dosage must be permanent. A dose lower than 160&nbsp;mg/kg/day or irregular intake may result in relapse of crises.</p><p>Children</p><p><em>Dyslexia</em> <em>in combination with appropriate measures such as speech therapy</em></p><p>The recommended dosage for school age children (from 8 years old) and adolescents is 3.2 g per day, that means 8 ml of 20% solution twice per day or 2 tablets of 800 mg in the morning and in the evening, usually during the whole period of the school year.</p><p><em>Prophylaxis and remission of sickle cell vaso-occlusive crises</em></p><p>For children from 3 years old onwards the prophylactic dosage is 160 mg/kg/per day divided into 4 divided doses. In case of remission a dose of 300 mg/kg/day is administered intravenously, divided into 4 divided doses. The prophylactic administration in sickle cell anaemia must be permanent.</p><p>A dose lower than 160/mg/kg/per day or an irregular intake may cause a relapse of the illness. Piracetam is administered to children with sickle cell anaemia indication in recommended daily doses (mg/kg &ndash; see above). Piracetam has been administered only to a limited number of children in the age range of 1-3 years.</p><p>Elderly</p><p>Adjustment of the dose is recommended in elderly patients with compromised renal function <em>(see Section Warnings and Precautions; Renal impairment below)</em>. For long term treatment in the elderly, regular evaluation of the creatinine clearance is required to allow dosage adaptation if needed.</p><p>Renal impairment</p><p>Piracetam is contraindicated in severe renal impairment (renal creatinine clearance of less than 20&nbsp;ml per minute) <em>(see Sections: Contraindications; Warnings and Precautions). </em>The daily dose must be individualised according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&rsquo;s creatinine clearance (Clcr) in ml/min is needed. The Clcr in ml/min may be estimated from serum creatinine (mg/dl) determination using the following formula:</p><p>Clcr = <u>[140 &ndash; age (<em>years</em>)] x weight (<em>kg</em>)</u> (x 0.85 for women)</p><p>72 x serum creatinine (<em>mg/dl</em>)</p><table border="1" cellspacing="0" cellpadding="0" style="width:96%"><tbody><tr><td style="vertical-align:top"><p><strong>Group</strong></p></td><td style="vertical-align:top"><p><strong>Creatinine clearance (ml/min)</strong></p></td><td style="vertical-align:top"><p><strong>Posology and frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Normal</strong></p></td><td style="vertical-align:top"><p>&gt; 80</p></td><td style="vertical-align:top"><p>usual daily dose, 2 to 4 sub-doses</p></td></tr><tr><td style="vertical-align:top"><p><strong>Mild</strong></p></td><td style="vertical-align:top"><p>50 - 79</p></td><td style="vertical-align:top"><p>2/3 usual daily dose, 2 or 3 sub-doses</p></td></tr><tr><td style="vertical-align:top"><p><strong>Moderate</strong></p></td><td style="vertical-align:top"><p>30 - 49</p></td><td style="vertical-align:top"><p>1/3 usual daily dose, 2 sub-doses</p></td></tr><tr><td rowspan="2"><p><strong>Severe</strong></p></td><td style="vertical-align:top"><p>20 - 29</p></td><td style="vertical-align:top"><p>1/6 usual daily dose, 1 single intake</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>contraindicated</p></td></tr><tr><td style="vertical-align:top"><p><strong>End-stage renal disease</strong></p></td><td style="vertical-align:top"><p>-</p></td><td style="vertical-align:top"><p>contraindicated</p></td></tr></tbody></table><p>Hepatic impairment</p><p>No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment, adjustment of dose is recommended (<em>see dose adjustment in Renal Impairment above).</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Piracetam is contraindicated in:
•	hypersensitivity to piracetam, other pyrrolidone derivatives or any of the excipients,
•	severe renal impairment (renal creatinine clearance of less than 20 ml per minute),
•	cerebral haemorrhage,
•	patients suffering from Huntington’s Chorea.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Effects on platelet aggregation</em></p><p>Due to the effect of piracetam on platelet aggregation, caution is recommended in patients with severe haemorrhage, patients at risk of bleeding such as gastrointestinal ulcer, patients with underlying disorders of haemostasis, patients with a history of haemorrhagic CVA, patients undergoing major surgery including dental surgery, and patients using anticoagulants or platelet antiaggregant drugs including low dose acetylsalicylic acid.</p><p><em>Renal insufficiency</em></p><p>Piracetam is eliminated via the kidneys and care should thus be taken in cases of renal insufficiency <em>(see Section Dosage and Administration)</em>.</p><p><em>Elderly</em></p><p>For long-term treatment in the elderly, regular evaluation of the creatinine clearance is required to allow dosage adaptation if needed <em>(see Section Dosage and Administration)</em></p><p><em>Discontinuation</em></p><p>Abrupt discontinuation of treatment should be avoided as this may induce myoclonic or generalised seizures in some myoclonic patients.</p><p><em>Sickle cell vaso-occlusive crises </em></p><p>For sickle cell indication, a dose lower than 160 mg/kg/day or irregular intake may result in relapse of crises.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacokinetic interactions</em></p><p>The drug interaction potential resulting in changes of piracetam pharmacokinetics is expected to be low because approximately 90% of the dose of piracetam is excreted in the urine as unchanged drug.</p><p><em>In vitro</em>, piracetam does not inhibit the human liver cytochrome P450 isoforms CYP 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 4A9/11 at concentrations of 142, 426 and 1422&nbsp;&micro;g/ml.</p><p>At 1422&nbsp;&micro;g/ml, minor inhibitory effects on CYP 2A6 (21%) and 3A4/5 (11%) were observed. However, the K<sub>i </sub>values for inhibition of these two CYP isoforms are likely to be well in excess of 1422&nbsp;&micro;g/ml. Therefore, metabolic interaction of piracetam with other drugs is unlikely.</p><p><em>Thyroid hormones</em></p><p>Confusion, irritability and sleep disorder have been reported during concomitant treatment with thyroid extract (T3 + T4).</p><p><em>Acenocoumarol</em></p><p>In a published single-blind study on patients with severe recurrent venous thrombosis, piracetam 9.6&nbsp;g/d did not modify the doses of acenocoumarol necessary to reach INR 2.5 to 3.5, but compared with the effects of acenocoumarol alone, the addition of piracetam 9.6&nbsp;g/d significantly decreased platelet aggregation, &beta;-thromboglobulin release, levels of fibrinogen and von Willebrand&#39;s factors (VIII: C; VIII: vW: Ag; VIII: vW: RCo) and whole blood and plasma viscosity.</p><p><em>Antiepileptic drugs</em></p><p>A 20&nbsp;g daily dose of piracetam over 4&nbsp;weeks did not modify the peak and trough serum levels of antiepileptic drugs (carbamazepine, phenytoin, phenobarbitone, valproate) in epileptic patients who were receiving stable doses.</p><p><em>Alcohol</em></p><p>Concomitant administration of alcohol had no effect on piracetam serum levels and alcohol levels were not modified by a 1.6&nbsp;g oral dose of piracetam.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Fertility</p><p>There are no relevant data available.</p><p>Pregnancy</p><p>Piracetam should not be used during pregnancy unless clearly necessary, when benefit exceeds the risks and the clinical condition of the pregnant mother requires treatment with piracetam. Piracetam crosses the placental barrier. Drug levels in the newborn are approximately 70% to 90% of maternal levels.</p><p>There are no adequate data from the use of piracetam in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/foetal development, parturition or post-natal development.</p><p>Lactation</p><p>Piracetam should not be used during breastfeeding or breastfeeding should be discontinued, while receiving treatment with piracetam. Piracetam is excreted in human breast milk. A decision must be made whether to discontinue breast-feeding or to discontinue piracetam therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In view of the undesirable side effects, which were observed after the administration of the prepartion, there is the possibility of influence on the ability to drive and to operate machinery and this should be taken into consideration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Clinical Trial and Post Marketing Data</p><p>Double-blind placebo-controlled clinical or pharmaco-clinical trials, of which quantified safety data are available, included more than 3000 subjects receiving piracetam, regardless of indication, dosage form, daily dosage or population characteristics.</p><p>Adverse drug reactions (ADRs) are listed below by MedDRA system organ class and by frequency.</p><p>Frequencies are defined as:</p><p>Very common &ge;1/10</p><p>Common &ge;1/100 to &lt;1/10</p><p>Uncommon &ge;1/1000 to &lt;1/100</p><p>Rare &ge;1/10000 to &lt;1/1000</p><p>Very rare &lt;1/10000</p><p>Not known (cannot be estimated from the available data).</p><p><em>&nbsp;</em></p><p><em>Blood and lymphatic system disorders</em></p><p><em>Not known:</em> haemorrhagic disorder</p><p><em>Immune system disorders</em></p><p><em>Not known:</em> anaphylactoid reaction, hypersensitivity</p><p><em>Psychiatric disorders</em></p><p><em>Common:</em> nervousness</p><p><em>Uncommon:</em> depression</p><p><em>Not known:</em> agitation, anxiety, confusion, hallucination</p><p><em>Nervous system disorders</em></p><p><em>Common:</em> hyperkinesia</p><p><em>Uncommon:</em> somnolence</p><p><em>Not known:</em> ataxia, balance disorder, epilepsy aggravated, headache, insomnia</p><p><em>Ear and labyrinth disorders</em></p><p><em>Not known:</em> vertigo</p><p><em>Vascular disorders</em></p><p><em>Rare: </em>thrombophlebitis (only for injectable form), hypotension (only for injectable form)</p><p><em>Gastrointestinal disorders</em></p><p><em>Not known:</em> abdominal pain, abdominal pain upper, diarrhoea, nausea, vomiting</p><p><em>Skin and subcutaneous tissue disorders</em></p><p><em>Not known:</em> angioneurotic oedema, dermatitis, pruritus, urticaria</p><p><em>General disorders and administration site conditions</em></p><p><em>Uncommon:</em> asthenia</p><p><em>Rare:</em> pyrexia (only for injectable form), injection site pain (only for injectable form)</p><p><em>Investigations</em></p><p><em>Common:</em> weight increased</p><p>&nbsp;</p><p>To report any side effect(s):</p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reporting hotline: 19999</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail : npc.drug@sfda.gov.sa</p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p><p><strong>-GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel: +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: saudi.safety@gsk.com</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://gskpro.com/en-sa/</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GlaxoSmithKline - Head Office, Jeddah</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tel:&nbsp; +966-12-6536666</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mobile: +966-56-904-9882</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Email: <u>gcc.medinfo@gsk.com</u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: <u>https://gskpro.com/en-sa/</u><u> </u></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; P.O. Box 55850, Jeddah 21544, Saudi Arabia</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms and signs</p><p>No additional adverse events specifically related to overdose have been reported with piracetam. The highest reported overdose with piracetam was oral intake of 75&nbsp;g wherein bloody diarrhoea with abdominal pain, was most probably related to the extreme high dose of sorbitol contained in the used formulation.</p><p>Treatment</p><p>There is no specific antidote for overdose with piracetam. Treatment for an overdose should be symptomatic and may include haemodialysis. The extraction efficiency of the dialyser is 50 to 60% for piracetam.</p><p>Further management should be as clinically indicated or as recommended by the national poisons centre, where available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group</p><p>Psychostimulants, agents used for ADHD and nootropics</p><p>ATC Code</p><p>N06BX03</p><p>Mechanism of Action</p><p>Available data suggest that piracetam basic mechanism of action is neither cell- nor organ-specific. Piracetam binds physically in a dose-dependent manner to the polar head of phospholipids membrane models, inducing the restoration of the membrane lamellar structure characterised by the formation of mobile drug-phospholipid complexes. This probably accounts for an improved membrane stability, allowing the membrane and transmembrane proteins to maintain or recover the three-dimensional structure or folding essential to exert their function. Piracetam has neuronal and vascular effects.</p><p>Pharmacodynamic effects</p><p><u>Neuronal effect </u></p><p>At the neuronal level, piracetam exerts its membrane activity in various ways. In animals, piracetam enhances a variety of types of neurotransmission, primarily through postsynaptic modulation of receptor density and activity. In both animals and man, the functions involved in cognitive processes such as learning, memory, attention and consciousness were enhanced, in the normal subject as well as in deficiency states, without the development of sedative or psychostimulant effects. Piracetam protects and restores cognitive abilities in animals and man after various cerebral insults such as hypoxia, intoxications and electroconvulsive therapy. It protects against hypoxia-induced changes in brain function and performance as assessed by electroencephalograph (EEG) and psychometric evaluations.</p><p><u>Vascular effects </u></p><p>Piracetam applies its haemorrhagic effect to thrombocytes, erythrocytes and the walls of the blood vessels by increasing the deformability of erythrocytes, reducing the aggregability of throbocytes, reduces the adhesion of erythrocytes to the walls of vessels and reduces capillary vasospasm.</p><p><em>Effects on the red blood cells</em></p><p>In patients with sickle cell anaemia, piracetam improves the deformability of the erythrocyte membrane, decreases blood viscosity, and prevents rouleaux formation.</p><p><em>Effects on platelets</em></p><p>In open studies in healthy volunteers and in patients with Raynaud&rsquo;s phenomenon, increasing doses of piracetam up to 12&nbsp;g was associated with a dose-dependent reduction in platelet functions compared with pre-treatment values (tests of aggregation induced by ADP, collagen, epinephrine and &beta; TG release), without significant change in platelet count. In these studies, piracetam prolonged bleeding time.</p><p><em>Effects on blood vessels</em></p><p>In animal studies, piracetam inhibited vasospasm and counteracted the effects of various spasmogenic agents. It lacked any vasodilatory action and did not induce &ldquo;steal&rdquo; phenomenon, nor low or no reflow, nor hypotensive effects.</p><p>In healthy volunteers, piracetam reduced the adhesion of RBCs to vascular endothelium and possessed also a direct stimulant effect on prostacycline synthesis in healthy endothelium.</p><p><em>Effects on coagulation factors</em></p><p>In healthy volunteers, compared with pre-treatment values, piracetam up to 9.6&nbsp;g reduced plasma levels of fibrinogen and von Willebrand&rsquo;s factors (VIII: C; VIII R: AG; VIII R: vW) by 30 to 40 %, and increased bleeding time.</p><p>In patients with both primary and secondary Raynaud phenomenon, compared with pre-treatment values, piracetam 8&nbsp;g/d during 6&nbsp;months reduced plasma levels of fibrinogen and von Willebrand&rsquo;s factors (VIII: C; VIII R: AG; VIII R: vW (RCF)) by 30 to 40 %, reduced plasma viscosity, and increased bleeding time.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetic profile of piracetam is linear and time-independent with low intersubject variability over a large range of doses. This is consistent with the high permeability, high solubility, and minimal metabolism of piracetam. Plasma half-life of piracetam is 5&nbsp;hours. It is similar in adult volunteers and in patients. It is increased in the elderly (primarily due to impaired renal clearance) and in subjects with renal impairment. Steady state plasma concentrations are achieved within 3&nbsp;days of dosing.</p><p>Absorption</p><p>Piracetam is rapidly and extensively absorbed following oral administration. In fasted subjects, the peak plasma concentrations are achieved 1&nbsp;hour after dosing. The absolute bioavailability of piracetam oral formulations is close to 100%. Food does not affect the extent of absorption of piracetam but it decreases C<sub>max</sub> by 17% and increases T<sub>max</sub> from 1 to 1.5&nbsp;hours. Peak concentrations are typically 84&nbsp;&micro;g/ml and 115&nbsp;&micro;g/ml following a single oral dose of 3.2&nbsp;g and repeat dose of 3.2&nbsp;g twice daily, respectively.</p><p>Distribution</p><p>Piracetam is not bound to plasma proteins and its volume of distribution is approximately 0.6&nbsp;l/kg. Piracetam crosses the blood brain barrier as it has been measured in cerebrospinal fluid following intravenous administration. In cerebrospinal fluid, the T<sub>max</sub> was achieved about 5&nbsp;hours post-dose and the half-life was about 8.5&nbsp;hours. In animals, piracetam highest concentrations in the brain were in the cerebral cortex (frontal, parietal and occipital lobes), in the cerebellar cortex and in the basal ganglia. Piracetam diffuses to all tissues except adipose tissues, crosses placental barrier, and penetrates the membranes of isolated red blood cells.</p><p>Metabolism</p><p>Piracetam is not known to be metabolized in the human body. This lack of metabolism is supported by the lengthy plasma half-life in anuric patients and the high recovery of parent compound in urine.</p><p>Elimination</p><p>The plasma half-life of piracetam in adults is about 5&nbsp;hours following either intravenous or oral administration. The apparent total body clearance is 80-90&nbsp;ml/min. The major route of excretion is via urine, accounting for 80 to 100% of the dose. Piracetam is excreted by glomerular filtration.</p><p>Linearity</p><p>The pharmacokinetics of piracetam are linear over the dose range of 0.8 to 12&nbsp;g. Pharmacokinetic variables like half-life and clearance are not changed with respect to the dose and the duration of treatment.</p><p>Special patient populations</p><p>Children</p><p>No formal pharmacokinetic study has been conducted in children.</p><p>Elderly</p><p>In the elderly, the half-life of piracetam is increased and the increase is related to the decrease in renal function in this population <em>(see Section Dosage and Administration)</em>.</p><p>Renal impairment</p><p>Piracetam clearance is correlated to creatinine clearance. It is therefore recommended to adjust the daily dose of piracetam based on creatinine clearance in patients with renal impairment <em>(see Section Dosage and Administration)</em>. In anuric End Stage Renal Disease subjects, the half-life of piracetam is increased up to 59 hours. The fractional removal of piracetam was 50 to 60% during a typical 4-hour dialysis session.</p><p>Hepatic impairment</p><p>The influence of hepatic impairment on the pharmacokinetics of piracetam has not been evaluated. Because 80 to 100% of the dose is excreted in the urine as unchanged drug, hepatic impairment solely would not be expected to have a significant effect on piracetam elimination.</p><p>Other patient characteristics</p><p>Gender</p><p>In a bioequivalence study comparing formulations at a dose of 2.4&nbsp;g, C<sub>max </sub>and AUC were approximately 30% higher in women (N=6) compared to men (N=6). However, clearances adjusted for body weight were comparable.</p><p>Race</p><p>Formal pharmacokinetic studies of the effects of race have not been conducted. Cross study comparisons involving Caucasians and Asians, however, show that pharmacokinetics of piracetam were comparable between the two races. Because piracetam is primarily renally excreted and there are no important racial differences in creatinine clearance, pharmacokinetic differences due to race are not expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>See Section </em><em>Pharmacodynamic effects.</em></p><p><strong>NON-CLINICAL INFORMATION</strong></p><p>The preclinical data indicate that piracetam has a low toxicity potential. Single dose studies showed no irreversible toxicity after oral doses of 10 g/kg in mice, rats and dogs. No target organ for toxicity was observed in repeated dose, chronic toxicity studies in mice (up to 4.8 g/kg/day) and in rats (up to 2.4 g/kg/day). Mild gastrointestinal effects (emesis, change in stool consistency, increased water consumption) were observed in dogs when piracetam was administered orally for one year at a dose increasing from 1 to 10 g/kg/day. Similarly, i.v. administration of up to 1 g/kg/day for 4-5 weeks in rats and dogs did not produce toxicity. <em>In vitro</em> and <em>in viv</em>o studies have shown no potential for genotoxicity and carcinogenicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Piracetam, 800 mg, film-coated tablet</strong></p><p>Macrogol 6000, Colloidal anhydrous silica, Magnesium stearate, Sodium</p><p>croscarmellose, Hydroxypropyl methylcellulose, Titanium dioxide (E171),</p><p>Macrogol 400</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the packaging
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>30 Film-coated tablets of piracetam 800 mg</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Not all presentations are available in every country</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no special requirements for use or handling of this product</p><p>&nbsp;</p><p><em>Nootropil </em><em>is a tr</em><em>ademark owned by or licensed to the GSK group of companies</em></p><p><em>&copy; 2020 GSK group of companies. All rights reserved.</em></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
UCB S.A. PHARMA SECTOR, BRAINE-L• AL LEUD. BELGIUM
MAH:
Glaxo Saudi Arabia Ltd.* Jeddah, KSA
Address: P.O. Box 22617 Jeddah 21416 – Kingdom of Saudi Arabia
*member of the GlaxoSmithKline group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version number: 03
Version date: 25 January 2017

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>